Wilmington, NC, 18 January 2021 – Evolved from over 15 years serving the biopharma industry, Catalyst Clinical Research formally launched two customized clinical service solutions in January — Catalyst Oncology and Catalyst Flex — to strengthen and expand the CRO’s partnerships with global life sciences companies. This launch is a key part of the company’s strategic growth plan for 2021 and provides clarity around the breadth and flexibility of Catalyst’s clinical development services.
The richer, more customized clinical offerings have been developed over several years of strategic growth during which Catalyst Clinical Research broadened its technical and therapeutic expertise and expanded its global footprint to better serve international clients. The company’s formalized offerings include:
A full-service, niche oncology CRO focused on next-generation cancer therapies, Catalyst Oncology offers an unparalleled depth of oncology expertise across all operational functions. The Oncology team offers skilled management of immuno-oncology and targeted therapies as well as expert oversight of complex study designs to help drive the next generation of novel therapies into the clinic and to cancer patients in need. Underpinned by best-in-class technologies, a data-driven approach, and flexible solutions, Catalyst Oncology partners with clients to listen, learn, and design customized clinical research solutions exclusively for the biotech market.
“We saw a real need for a more responsive, nimble CRO that can serve the unique and dynamic needs of oncology-focused biotech companies,” says Andrew Zupnick, Vice President of Oncology Drug Development, Catalyst Oncology. “Too often, sponsors are forced into a ‘one-size-fits-all’ model that lacks therapeutic depth across all functions and fails to provide flexibility in meeting the needs of a rapidly shifting next-generation cancer development program.”
With more than a decade of experience across multiple therapeutic areas, Catalyst Flex offers functional services and resourcing solutions from a breadth of experience and depth of candidates. The Flex team creates “fit for purpose” solutions providing a flexible and scalable model to assist clients with enhanced capabilities helping to improve the lives of patients worldwide. Catalyst Flex commits to listening to client priorities while creating strategic approaches to clinical development, biometrics, and safety services for the broader life sciences industry.
Scot Stubenhofer, Vice President of Growth Strategy, Catalyst Flex, says the new services are constructed with our ‘customer-first’ culture. “True innovation only takes place when you are committed to listening to customers’ needs and finding flexible solutions that get results,” Stubenhofer. “We hold these tenets dear in everything we do, and we will never compromise on them.”
The launch of the focused offerings reflects the company’s plan for a new growth phase in oncology and in resourcing solutions. This growth is directly related to increased demand by our clients and strategic acquisitions of Acumen Healthcare Solutions (AHS) and Ce3, Inc. during 2020.
Catalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry through two established solutions: Catalyst Flex and Catalyst Oncology. With over 400 staff and offices in the US and EU, the company provides multi-therapeutic global resourcing and functional services through Catalyst Flex and a full-service oncology CRO offering through Catalyst Oncology. The company’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping them drive breakthrough clinical development studies leveraging Catalyst’s expert teams and innovative technologies.
Catalyst is a portfolio company of NovaQuest Capital Management, LLC, a leading healthcare and life sciences investment firm.